Sign in

CIK 0001609809

  • Non-accelerated filer
  • Smaller reporting company

Seres Therapeutics, Inc.

Sign in to watch
Ticker
MCRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
274326290
Phone
+1 617-945-9626
Business address
200 SIDNEY STREET, CAMBRIDGE, MA, 02139
Former names
Seres Therapeutics, Inc., Seres Health, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$795
in 4 filings, $795 under 10b5-1 plans

Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 39 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2020-03-20 Biondi Paul Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2020-01-29 Shaff Eric D. President CFO Grant or award · STOCK OPTION (RIGHT TO BUY) +1,000,000 1,000,000
2020-01-29 Chapman Marcus Grant or award · STOCK OPTION (RIGHT TO BUY) +125,000 125,000
2020-01-29 DesRosier Thomas Chief Legal Officer and EVP Grant or award · STOCK OPTION (RIGHT TO BUY) +350,000 350,000
2020-01-29 Henn Matthew R. Grant or award · STOCK OPTION (RIGHT TO BUY) +300,000 300,000
2020-01-29 Aunins John G. Chief Technology Officer & EVP Grant or award · STOCK OPTION (RIGHT TO BUY) +300,000 300,000
2020-01-26 Shaff Eric D. CEO and President Exercise or conversion +20,000 32,842
2020-01-26 Shaff Eric D. CEO and President Exercise or conversion · RESTRICTED STOCK UNITS −20,000 0
2020-01-26 DesRosier Thomas Chief Legal Officer and EVP Exercise or conversion +25,000 41,054
2020-01-26 DesRosier Thomas Chief Legal Officer and EVP Exercise or conversion · RESTRICTED STOCK UNITS −25,000 0
2020-01-26 Henn Matthew R. Exercise or conversion +7,500 12,000
2020-01-26 Henn Matthew R. Exercise or conversion · RESTRICTED STOCK UNITS −7,500 0
2020-01-26 Aunins John G. Chief Technology Officer & EVP Exercise or conversion +12,500 105,250
2020-01-26 Aunins John G. Chief Technology Officer & EVP Exercise or conversion · RESTRICTED STOCK UNITS −12,500 0
2019-11-22 Chapman Marcus Sale −3,400 $3.91 $13K 8,600
2019-11-01 Chapman Marcus Exercise or conversion +12,000 12,000
2019-11-01 Chapman Marcus Exercise or conversion · Restricted Stock Units −12,000 0
2019-08-05 Berenson Stephen Director Grant or award · Stock Option (Right to Buy) +30,000 30,000
2019-06-18 AFEYAN NOUBAR Director Purchase +4,444,444 $2.25 $10.0M 4,444,444
2019-06-18 AFEYAN NOUBAR Director Purchase +4,444,444 $2.25 $10.0M 4,444,444

Page 24 of 34 · 662 trades